ID27845A - Turunan tetrahidrokuilina sebagai antagonis glisilina - Google Patents

Turunan tetrahidrokuilina sebagai antagonis glisilina

Info

Publication number
ID27845A
ID27845A IDW20010061A ID20010061A ID27845A ID 27845 A ID27845 A ID 27845A ID W20010061 A IDW20010061 A ID W20010061A ID 20010061 A ID20010061 A ID 20010061A ID 27845 A ID27845 A ID 27845A
Authority
ID
Indonesia
Prior art keywords
tetrahidrokuilina
glisilina
antagonists
decreased
tetrahidrokuilina decreased
Prior art date
Application number
IDW20010061A
Other languages
English (en)
Inventor
Romano Di Fabio
Original Assignee
Glaxo Wellcome Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9812408.4A external-priority patent/GB9812408D0/en
Priority claimed from GBGB9812410.0A external-priority patent/GB9812410D0/en
Application filed by Glaxo Wellcome Spa filed Critical Glaxo Wellcome Spa
Publication of ID27845A publication Critical patent/ID27845A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IDW20010061A 1998-06-10 1999-06-08 Turunan tetrahidrokuilina sebagai antagonis glisilina ID27845A (id)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9812408.4A GB9812408D0 (en) 1998-06-10 1998-06-10 Heterocyclic compounds
GBGB9812410.0A GB9812410D0 (en) 1998-06-10 1998-06-10 Heterocyclic derivatives

Publications (1)

Publication Number Publication Date
ID27845A true ID27845A (id) 2001-04-26

Family

ID=26313826

Family Applications (1)

Application Number Title Priority Date Filing Date
IDW20010061A ID27845A (id) 1998-06-10 1999-06-08 Turunan tetrahidrokuilina sebagai antagonis glisilina

Country Status (33)

Country Link
US (3) US6362199B1 (id)
EP (1) EP1086093B1 (id)
JP (1) JP2002517492A (id)
KR (1) KR100586762B1 (id)
CN (1) CN1173970C (id)
AP (1) AP2000002008A0 (id)
AR (1) AR018632A1 (id)
AT (1) ATE301650T1 (id)
AU (1) AU753867B2 (id)
BG (1) BG105123A (id)
BR (1) BR9911145A (id)
CA (1) CA2334727C (id)
CO (1) CO5080785A1 (id)
CZ (1) CZ293605B6 (id)
DE (1) DE69926632T2 (id)
DK (1) DK1086093T3 (id)
EA (1) EA003276B1 (id)
EE (1) EE200000733A (id)
ES (1) ES2249010T3 (id)
HR (1) HRP20000845A2 (id)
HU (1) HUP0102767A3 (id)
ID (1) ID27845A (id)
IL (2) IL140062A0 (id)
IS (1) IS5746A (id)
MY (1) MY125037A (id)
NO (1) NO321904B1 (id)
NZ (1) NZ508638A (id)
OA (1) OA11564A (id)
PE (1) PE20000724A1 (id)
PL (1) PL197160B1 (id)
TR (1) TR200003652T2 (id)
TW (1) TWI229079B (id)
WO (1) WO1999064411A1 (id)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
DE10000311A1 (de) 2000-01-05 2001-07-12 Gruenenthal Gmbh Aminomethyl-Phonyl-Cyclohexanonderivate
DE10005302A1 (de) * 2000-02-07 2002-01-17 Gruenenthal Gmbh Substituierte 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137488A1 (de) * 2001-08-03 2003-02-20 Gruenenthal Gmbh Salze substituierter 1,2,3,4-Tetrahydrochinolin-2-carbonsäurederivate
DE10137487A1 (de) 2001-08-03 2003-03-27 Gruenenthal Gmbh Substituierte 5,6,6a,11b-Tetrahydro-7-oxa-6-aza- benzo[c]fluoren-6-carbonsäurederivate
PL376156A1 (en) * 2002-10-04 2005-12-27 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
GB0327912D0 (en) * 2003-12-02 2004-01-07 Glaxo Group Ltd Medicament
BRPI0608553A2 (pt) * 2005-02-24 2010-01-12 Millennium Pharm Inc antagonistas de receptor de pgd2 para o tratamento de doenças inflamatórias

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2024516C1 (ru) * 1989-02-02 1994-12-15 Яманути Фармасьютикал Ко., Лтд. Способ получения производного тетрагидробензимидазола или его фармацевтически приемлемой соли
US4902695A (en) * 1989-02-13 1990-02-20 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5231102A (en) * 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
IL93610A0 (en) * 1989-03-08 1990-12-23 Merck Sharp & Dohme Tetrahydroquinoline derivatives,their preparation and pharmaceutical compositions containing them
US5529999A (en) 1994-03-04 1996-06-25 Eli Lilly And Company Antitumor compositions and methods of treatment
CZ292379B6 (cs) 1995-09-29 2003-09-17 Glaxo Wellcome Spa Tetrahydrochinolinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
GB9617305D0 (en) * 1996-08-17 1996-09-25 Glaxo Wellcome Spa Heterocyclic compounds
MY125037A (en) * 1998-06-10 2006-07-31 Glaxo Wellcome Spa 1,2,3,4 tetrahydroquinoline derivatives

Also Published As

Publication number Publication date
PL344694A1 (en) 2001-11-19
IL140062A (en) 2007-05-15
HUP0102767A3 (en) 2003-01-28
PL197160B1 (pl) 2008-03-31
HUP0102767A2 (hu) 2001-12-28
ATE301650T1 (de) 2005-08-15
ES2249010T3 (es) 2006-03-16
EE200000733A (et) 2002-06-17
KR100586762B1 (ko) 2006-06-08
CO5080785A1 (es) 2001-09-25
US6413985B1 (en) 2002-07-02
CN1173970C (zh) 2004-11-03
EP1086093B1 (en) 2005-08-10
NZ508638A (en) 2003-08-29
CA2334727A1 (en) 1999-12-16
CA2334727C (en) 2009-08-04
US6362199B1 (en) 2002-03-26
US20020169186A1 (en) 2002-11-14
DK1086093T3 (da) 2005-11-28
NO20006227L (no) 2001-02-08
NO321904B1 (no) 2006-07-17
HK1034079A1 (en) 2001-10-12
EA003276B1 (ru) 2003-04-24
DE69926632D1 (de) 2005-09-15
BR9911145A (pt) 2001-03-06
IS5746A (is) 2000-11-30
EA200001165A1 (ru) 2001-06-25
IL140062A0 (en) 2002-02-10
TWI229079B (en) 2005-03-11
JP2002517492A (ja) 2002-06-18
BG105123A (en) 2001-11-30
CN1311785A (zh) 2001-09-05
AU753867B2 (en) 2002-10-31
TR200003652T2 (tr) 2001-04-20
AR018632A1 (es) 2001-11-28
AP2000002008A0 (en) 2000-12-31
US6495566B2 (en) 2002-12-17
US20020052391A1 (en) 2002-05-02
KR20010052722A (ko) 2001-06-25
WO1999064411A1 (en) 1999-12-16
OA11564A (en) 2004-05-24
AU4509299A (en) 1999-12-30
PE20000724A1 (es) 2000-08-17
MY125037A (en) 2006-07-31
CZ293605B6 (cs) 2004-06-16
DE69926632T2 (de) 2006-01-19
CZ20004587A3 (en) 2001-05-16
EP1086093A1 (en) 2001-03-28
HRP20000845A2 (en) 2001-10-31
NO20006227D0 (no) 2000-12-07

Similar Documents

Publication Publication Date Title
EP0986385A4 (en) GONADORELIN ANTAGONISTS
NO20016115L (no) Substituerte heterosykelkondenserte gamma-karbolin
PT1224180E (pt) Azois substituidos
ID29066A (id) Turunan fenilglisina
ID27423A (id) Turunan kuinolin
ID23234A (id) Turunan-turunan benzosulfona
NO990113D0 (no) Flerskrog-fart°y
ID27484A (id) Turunan adenosina
NO992692L (no) Nefadozon doseringsform
ID27547A (id) Turunan kuinolin
ID23761A (id) Trisiklik tersubstitusi
EE200000171A (et) Uued NPY antagonistid
NO994626D0 (no) Substituerte benzamider
DE69908262D1 (de) Sprühbehälter
ID26223A (id) Antagonis reseptor vitronektin
ID29914A (id) Senyawa benzensulfonamida heterosiklik sebagai antagonis bradikinin
ID26665A (id) Antagonis vla-4
NO20010873L (no) Mikropartikkel-blanding
ID22838A (id) Oksazolidina sebagai antagonis 5-ht2a
ID23219A (id) Trisiklik tersubstitusi
ID28811A (id) Antagonis reseptor vitronektin
FI19992609L (fi) Uusi koostumus
NO20022927D0 (no) Substituerte pyrrazoler
ID28356A (id) Turunam tiazola
DE59911610D1 (de) Substituierte benzoylcyclohexandione